The MAFLD Screening Gap in Australia (and What Clinics Can Do Next)
Why metabolic liver disease is under-detected in Australian primary care, how risk stratification is evolving, and where guided elastography fits in the pathway.
Metabolic dysfunction-associated fatty liver disease (MAFLD, also discussed as MASLD in some literature) is now one of the most common chronic liver conditions in Australia. Yet many patients still reach specialist review only after enzymes drift upward for years—or after fibrosis has progressed further than it needed to.
This article summarises the practical screening gap: what is happening in community practice, why traditional pathways stall, and how Australian clinics are tightening the pathway with non-invasive staging tools.
Why the gap exists
MAFLD is often silent. Patients may have normal ALT episodes, few symptoms, and busy GPs juggling diabetes, obesity, and cardiovascular prevention in short consultations.
FIB-4 and similar calculators help prioritise who needs more testing, but indeterminate results are common. Without a clear next step, patients can remain in a ‘watch and wait’ loop.
Access to elastography has historically been uneven—concentrated in hospitals or imaging centres—so primary care teams have not always had a fast, repeatable way to stage fibrosis at the point of care.
What is changing in Australian workflows
National conversations about early liver risk stratification are aligning with diabetes and obesity initiatives. The goal is not more testing for everyone—it is smarter triage for patients who are most likely to benefit.
When elastography is available in community settings, clinicians can convert ‘indeterminate bloodwork’ into an objective stiffness signal, paired with clinical context.
Guided elastography systems aim to reduce failed acquisitions in challenging body habitus by visualising placement—an important issue in real-world Australian cohorts.
How Elastography Australia fits (high level)
Elastography Australia is positioned as a guided liver elastography platform intended for clinicians who want visualised measurements and efficient workflows. It is not a replacement for clinical judgement or specialist care when red flags exist.
If you are evaluating devices, the comparison that usually matters in Australia is not brochure specs alone—it is operator workflow, obese-patient success rates, training depth, and integration with your practice model.
Related reading
Explore our clinical guides on MAFLD screening in Australia and liver fibrosis staging, or compare guided vs blind elastography approaches on the education hub.